The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta-analysis
Publication in refereed journal


摘要Aim Cases of cardiotoxicity related to trastuzumab have been reported. This systematic review and meta-analysis evaluated the risk of atrial fibrillation (AF) in patients of breast cancer treated with trastuzumab. Methods PubMed and EMBASE were searched until September 2017 for articles that investigated AF incidence in patients receiving trastuzumab for breast cancer. Results A total of 15 studies involving 8124 patients treated with trastuzumab were included. Of the total cohort, 37 patients suffered from AF, giving rise to an incidence of 1.22% (95% confidence interval [CI]: 0.56%-2.68%). No significant difference in the incidence of AF was found between ado-trastuzumab emtansine (0.95%, 95% CI: 0.36%-2.52%) and trastuzumab groups (1.32%, 95% CI: 0.52%-3.34%), trastuzumab combined with other antineoplastic agents (2.09%, 95% CI: 1.16%-3.73%) and trastuzumab alone (0.36%, 95% CI: 0.04%-3.08%), prior exposure to anthracyclines (1.72%, 95% CI: 0.75%-3.88%) and no prior exposure (1.03%, 95% CI: 0.30%-3.51%), and radiotherapy (1.26%, 95% CI: 0.68%-2.33%) vs. no radiotherapy (1.21%, 95% CI: 0.35%-4.14%). Conclusions Atrial fibrillation incidence in breast cancer patients receiving trastuzumab was around 1.2%. It was not influenced by the formulation of trastuzumab, the additional use of neoplastic agents, anthracycline exposure status, or concurrent radiotherapy.
著者Yuan M, Tse G, Zhang ZW, Han X, Wu WKK, Li GP, Xia YL, Liu T
期刊名稱Cardiovascular Therapeutics
關鍵詞atrial fibrillation, breast cancer, cardiotoxicity, drug safety, trastuzumab
Web of Science 學科類別Cardiac & Cardiovascular Systems;Pharmacology & Pharmacy;Cardiovascular System & Cardiology;Pharmacology & Pharmacy

上次更新時間 2021-23-02 於 01:27